Nov. 3, 2004 – Cambrios Technologies Corp. has been granted a license to technology that it considers integral to developing a biologically based platform for the electronics industry, according to a news release.
The Cambridge, Mass.-based firm, which plans by year’s end to move primary operations to Palo Alto, Calif., said the deal includes an option to maintain an exclusive license to Dyax Corp.’s peptide phage display technology for synthesizing and assembling materials and structures used in electronic applications. Dyax scientists in the late 1980s discovered and patented bacteriophage display technology, which is used in drug discovery, diagnostic imaging and other biological areas. Bacteriophage, or phage is a virus that infects only bacteria.
Cambrios co-founder Angela Belcher saw the potential for using phage techniques to synthesize self-assembling nanostructures.